Saag M S
Department of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, 35294-2050, USA.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16 Suppl 1:S3-13. doi: 10.1097/00042560-199701001-00002.
A number of virologic and immunologic markers, including serum human immunodeficiency virus (HIV)-1 p24 antigen levels, quantitative HIV-1 microculture of plasma or peripheral blood mononuclear cells, and CD4 cell counts, have been used over the past decade to monitor progression of HIV infection. Although these markers are useful, they have not provided a reliable means of assessing prognosis at all stages of the disease or response to antiretroviral treatment. New molecular techniques are now available that measure viral load in HIV-infected patients by detecting and quantifying virion-associated RNA circulating in plasma. These plasma HIV-1 RNA levels appear to correlate with the clinical disease stage and reflect the response to antiretroviral treatment. Because recent studies have demonstrated that baseline plasma HIV-1 RNA levels and changes in these levels are predictive of clinical outcome, it is strongly recommended that these markers be measured routinely and used as a guide in the management of all patients with HIV disease.
在过去十年中,人们使用了许多病毒学和免疫学标志物来监测艾滋病毒感染的进展,包括血清人类免疫缺陷病毒(HIV)-1 p24抗原水平、血浆或外周血单核细胞的HIV-1定量微培养以及CD4细胞计数。尽管这些标志物很有用,但它们并未提供一种在疾病的所有阶段评估预后或对抗逆转录病毒治疗反应的可靠方法。现在有了新的分子技术,通过检测和定量血浆中循环的病毒体相关RNA来测量HIV感染患者的病毒载量。这些血浆HIV-1 RNA水平似乎与临床疾病阶段相关,并反映对抗逆转录病毒治疗的反应。由于最近的研究表明,基线血浆HIV-1 RNA水平及其变化可预测临床结果,因此强烈建议常规检测这些标志物,并将其用作所有HIV疾病患者管理的指导。